Anti-tumor effects of RTX-240: an engineered red blood cell expressing 4-1BB ligand and interleukin-15

Recombinant agonists that activate co-stimulatory and cytokine receptors have shown limited clinical anticancer utility, potentially due to narrow therapeutic windows, the need for coordinated activation of co-stimulatory and cytokine pathways and the failure of agonistic antibodies to recapitulate...

Descripción completa

Detalles Bibliográficos
Autores principales: McArdel, Shannon L., Dugast, Anne-Sophie, Hoover, Maegan E., Bollampalli, Arjun, Hong, Enping, Castano, Zafira, Leonard, Shannon Curtis, Pawar, Sneha, Mellen, Jennifer, Muriuki, Kelvin, McLaughlin, Douglas C., Bayhi, Nicholas, Carpenter, Christopher L., Turka, Laurence A., Wickham, Thomas J., Elloul, Sivan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360899/
https://www.ncbi.nlm.nih.gov/pubmed/34244816
http://dx.doi.org/10.1007/s00262-021-03001-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360899/
https://www.ncbi.nlm.nih.gov/pubmed/34244816
http://dx.doi.org/10.1007/s00262-021-03001-7

Ejemplares similares